SARATOGA, Calif. – January 10, 2011 – In an analysis of 150 putative myelin repair targets identified by the Myelin Repair Foundation (MRF) collaborative research team since 2004, more than 40 already have approved drugs on the market or are currently in clinical development by several biopharmaceutical companies for non-Multiple Sclerosis disease indications (See Figures 1 & 2.). The analysis also shows that 31 additional MRF targets are in the discovery process or preclinical stage for other indications.
The analysis of publicly available data was conducted by the MRF Drug Discovery Advisory Board of outside biopharmaceutical experts to aid the Foundation in prioritizing the overwhelming number of targets generated in its funded laboratories at Stanford University, the University of Chicago, Northwestern University, Case Western Reserve University, University of
California-San Francisco and the University of Melbourne, Victoria, Australia.
http://www.myelinrepair.org/documents/M ... nities.pdf